TGM2 and glioblastoma: Treatments with TG2 inhibitors induced a shift toward a pro-apoptotic profile in GBM cell lines, with an enhancement in the levels of pro-apoptotic BH-3only protein, BIM, and a reduction of levels of anti-apoptotic proteins (i.e., survivin, phosphorylated Akt, Bad, and GSK-3β).